Français
ItalianoBond Royalty Pharma 1.2% ( US78081BAH69 ) in USD
| Issuer | Royalty Pharma | ||||||||
| Market price | 97.87 % ▼ | ||||||||
| Country |  United States
|
||||||||
| ISIN code |
 US78081BAH69 ( in USD )
|
||||||||
| Interest rate | 1.2% per year ( payment 2 times a year) | ||||||||
| Maturity | 02/09/2025 - Bond has expired | ||||||||
|
Prospectus brochure in PDF format |
|||||||||
| Minimal amount | 2 000 USD | ||||||||
| Total amount | 999 962 000 USD | ||||||||
| Cusip | 78081BAH6 | ||||||||
| Standard & Poor's ( S&P ) rating | BBB- ( Lower medium grade - Investment-grade ) | ||||||||
| Moody's rating | Baa2 ( Lower medium grade - Investment-grade ) | ||||||||
| Detailed description |
Royalty Pharma is a biopharmaceutical company that invests in and manages royalties from marketed pharmaceutical and biotechnology products. The Bond issued by Royalty Pharma ( United States ) , in USD, with the ISIN code US78081BAH69, pays a coupon of 1.2% per year. The coupons are paid 2 times per year and the Bond maturity is 02/09/2025 The Bond issued by Royalty Pharma ( United States ) , in USD, with the ISIN code US78081BAH69, was rated Baa2 ( Lower medium grade - Investment-grade ) by Moody's credit rating agency. The Bond issued by Royalty Pharma ( United States ) , in USD, with the ISIN code US78081BAH69, was rated BBB- ( Lower medium grade - Investment-grade ) by Standard & Poor's ( S&P ) credit rating agency. |
||||||||
| |||||||||